Research programme: nanomedicines - Pfizer/Merck & CoAlternative Names: KSP Accurin™ - Pfizer/Merck & Co; KSP inhibitors - Pfizer/Merck & Co; PLK1 Accurin™ - Pfizer/Merck & Co; PLK1 inhibitors - Pfizer/Merck & Co
Latest Information Update: 25 Jan 2017
At a glance
- Originator BIND Therapeutics; Merck & Co
- Developer Merck & Co; Pfizer
- Mechanism of Action KIF11 protein inhibitors; Polo-like kinase 1 inhibitors; Proto oncogene protein c-akt inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer